{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-024621","form_type":"8-K","ticker":"CLYM","cik":"0001768446","company_name":"Climb Bio, Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.041870+00:00","generated_at":"2026-06-21T20:48:39.135281+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Eliem Therapeutics Q3 net loss $9.7M, cash $129.6M; ETX-155 Phase 2a MDD trial to start Q1 2023","bullets":["Net loss of $9.7M for Q3 2022 (vs. $9.6M Q3 2021); R&D expenses $4.3M, G&A $4.5M.","Cash and marketable securities $129.6M as of Sep 30, 2022; cash runway expected to fund operations into 2025.","ETX-155 Phase 2a MDD trial to initiate in Q1 2023 with 60-mg dose; topline data expected H2 2024.","Kv7.2/3 program: IND-enabling safety studies for two pre-candidates expected Q1 2023; Phase 1 studies planned H1 2024.","Phase 1 PK trial completed; selected 60-mg dose over 75-mg due to marginal additional benefit."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-024621","json":"https://secwatch.observer/filing/0000950170-22-024621.json","markdown":"https://secwatch.observer/filing/0000950170-22-024621.md","text":"https://secwatch.observer/filing/0000950170-22-024621.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768446/000095017022024621/0000950170-22-024621-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768446/000095017022024621/elym-20221114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T20:48:39.135281+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ffe26c902f8a196c84c4fc14a0140733fbebd51e","claim":"Climb Bio, Inc. reported the quarter ended September 30, 2022 results: net income $9.7 million.","evidence_excerpt":"Net loss was $9.7 million for the three months ended September 30, 2022, compared to $9.6 million for the same period in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1768446/000095017022024621/0000950170-22-024621-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Net income","value":"$9.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}